Jan Gaertig
YOU?
Author Swipe
View article: Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity
Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity Open
Background & Aims: Atezolizumab/bevacizumab (atezo/bev) has revolutionized the standard of care for patients with unresectable hepatocellular carcinoma (HCC). However, only a subgroup of patients responds to atezo/bev and derives durable c…
View article: Supplementary Figure 8 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 8 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 8: Immunohistochemistry of mucosal tissues from irColitis and ulcerative colitis patients
View article: Data from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Data from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Although initially assumed to be similar, immune checkpoint inhibitor (ICI)–induced autoimmunity can differ from spontaneous autoimmune disease in regard to clinical presentation, pathogenesis, and therapy. Despite limited pathogenetic und…
View article: Supplementary Table 2 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Table 2 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
List of all differentially expressed genes and enriched pathways for gene expression analyses
View article: Supplementary Table 1 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Table 1 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Table 1: Patient characteristics
View article: Supplementary Table 3 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Table 3 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Table 3: List of FACS antibodies with respective antigens, fluorophores and clones
View article: Supplementary Figure 6 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 6 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 6: Activation and exhaustion marker co-expression on T cell subsets of irColitis and ulcerative colitis patients
View article: Supplementary Figure 2 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 2 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 2: Transcriptional analysis of irColitis and ulcerative colitis dependent on severity
View article: Supplementary Figure 5 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 5 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 5: Activation and exhaustion marker expression on T cell subsets of irColitis and ulcerative colitis patients
View article: Supplementary Figure 7 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 7 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 7: DC subset distribution in irColitis and ulcerative colitis patients
View article: Supplementary Figure 4 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 4 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 4: Representative gating strategies of FACS panels
View article: Supplementary Figure 3 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 3 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 3: Transcriptional analysis of healthy PBMC compared to irColitis PBMC
View article: Supplementary Figure 1 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
Supplementary Figure 1 from Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis Open
Supplementary Figure 1: Transcriptional analysis of healthy colon mucosa compared to mucosa of irColitis and ulcerative colitis patients